Dr. Datsons Labs shines on plan to partner with Clinton Foundation

10 Mar 2015 Evaluate

Dr. Datasons Labs is currently trading at Rs. 8.52, up by 0.34 points or 4.16% from its previous closing of Rs. 8.18 on the BSE.

The scrip opened at Rs. 8.32 and has touched a high and low of Rs. 8.88 and Rs. 8.30 respectively. So far 1089014 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 70.80 on 10-Mar-2014 and a 52 week low of Rs. 6.03 on 25-Feb-2015.

Last one week high and low of the scrip stood at Rs. 8.88 and Rs. 7.22 respectively. The current market cap of the company is Rs. 93.58 crore.

The institutions and non-institutions held 38.87% and 61.13% stake in the company, respectively.

Indian Drug maker Dr. Datsons Labs has received the proposal to supply the Artemisinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs will be making a significant deal though there is a minimum pricing that the company will be working on.

The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipea & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.

Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.

 

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×